.jpg)
2 hours ago
3
Article content
VANCOUVER, British Columbia, April 20, 2026 (GLOBE NEWSWIRE) — ViewsML, a company building the computational layer for biomarker discovery by transforming tissue analysis from a lab process into software, today announced the completion of an oversubscribed $4.9M seed funding round led by Wittington Ventures. Additionally, new investors Continuum Health Ventures and Mayo Clinic contributed alongside repeat investors RiSC Capital, Debiopharm, WUTIF, Defined, and e-Fund.
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
Article content
This funding reflects the investment community’s recognition of the significance of ViewsML’s technology and its development of the world’s first virtual biomarker library using artificial intelligence to generate per-cell biomarker spatial insights from pathology images without the need for laboratory staining.
Article content
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
As demand for scalable, high-resolution biomarker data grows across drug development and diagnostics, traditional staining workflows have become a critical bottleneck. Virtual biomarker staining represents a fundamental shift in how immunostaining is generated and analyzed, enabling an entirely new paradigm for assay development. ViewsML is leading this transformation through a scalable computational platform that converts a traditionally lab-bound process into software via its first-of-its-kind virtual biomarker library.
Article content
Through strategic collaborations with leading healthcare institutions, diagnostic companies, and biopharma organizations, the company is positioned to accelerate adoption across both research and clinical applications. The capital will be used to accelerate commercialization of ViewsML’s AI-driven virtual biomarker staining platform; expand its strategic partnerships; advance clinical validation of virtual biomarker panels; and grow the company’s engineering, scientific, and commercial teams.
Article content
Article content
“Biomarkers are foundational to how we understand and treat disease, yet the way we measure them remains constrained by legacy approaches. ViewsML is redefining how biomarkers are measured and analyzed – unlocking a step-change in speed, scale, and accessibility across research and clinical settings,” said Zeeshan Ali, Partner, Wittington Ventures. “Virtual staining has the potential to accelerate workflows, lower costs, and unlock new applications across translational research, diagnostics, clinical trials and emerging areas such as neurodegenerative disease – driving faster insights and improved patient outcomes.”
Article content
“We’re building the computational layer for next-generation diagnostics, and are excited to partner with Wittington Ventures and work with Mayo Clinic to accelerate that vision,” said Kenneth To, CEO, ViewsML. “This capital will enable us to fast-track our efforts to revolutionize immunohistochemistry (IHC). By building the world’s first virtual biomarker library, we’re going to empower scientists and clinicians to analyze biomarker staining in minutes rather than the traditional days or weeks.”
English (US)